Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GNG2 | P59768 | 1/20 | 0.30 |
| ▸ | GNB1 | P62873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132527 | 1.00 | HTR2A (0.33) | HTR2ASLC6A4EPAS1FFAR1HTR2C | |
| SCHEMBL20554321 | 0.85 | MAPT (0.35) | HTR2ASLC6A4HTR2CHTR2BSLC6A2 | |
| SCHEMBL30132604 | 0.85 | MAPT (0.35) | HTR2ASLC6A4HTR2CHTR2BSLC6A2 | |
| SCHEMBL20554109 | 0.82 | L3MBTL1 (0.41) | HTR2ASLC6A4LMNA | |
| SCHEMBL20554813 | 0.78 | ALOX5AP (0.39) | — | |
| SCHEMBL20554059 | 0.77 | FGFR4 (0.34) | FFAR1 | |
| SCHEMBL30132493 | 0.77 | FGFR4 (0.34) | FFAR1 | |
| SCHEMBL30132672 | 0.74 | MAPK14 (0.39) | HTR2AHTR2CHTR2BLMNAHPGD | |
| SCHEMBL20554295 | 0.74 | MAPK14 (0.39) | HTR2AHTR2CHTR2BLMNAHPGD | |
| SCHEMBL20554374 | 0.72 | MAPT (0.36) | HTR2ASLC6A4HTR2CHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | HTR2A 1733/4885SLC6A4 2627/4885EPAS1 1513/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | HTR2A 1736/4885SLC6A4 2767/4885EPAS1 1533/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | HTR2A 1319/4885SLC6A4 2664/4885EPAS1 1326/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | HTR2A 1342/4885SLC6A4 2506/4885EPAS1 1263/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | HTR2A 1319/4885SLC6A4 2664/4885EPAS1 1326/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | HTR2A 1342/4885SLC6A4 2506/4885EPAS1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.